Analyst: Infuse fallout could lead to Medtronic selling spine biz

A Wall Street analyst has speculated that Medtronic's woes over its blockbuster Infuse product might lead the medical device company to pull the plug on the entire spinal business. News

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.